Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer

The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.

Study Type: Interventional

Study Design: Endpoint Classification: Efficacy Study

Intervention Model: Single Group Assignment

Masking: Open Label

Primary Purpose: Treatment

Official Title: An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One or More Cycles in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy

Enrollment: 220

Study Start Date: December 2008

Study Completion Date: July 2013

Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)

Arms:

Experimental: Degarelix 240 mg / 80 mg